Grass pollen allergen solution - Allergopharma
Latest Information Update: 02 Nov 2015
At a glance
- Originator Allergopharma
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Seasonal allergic rhinitis
Most Recent Events
- 13 May 2011 Phase III development is ongoing in Germany